NCT04174365View on ClinicalTrials.gov

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

119

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

August 8, 2022

Study Completion Date

September 9, 2022

Conditions

Irritability Associated With Autism Spectrum Disorder (ASD)

Interventions

DRUG

Brexpiprazole

Oral tablet; take once daily

DRUG

Placebo

Administered orally daily for up to Week 8.

Trial Locations (1)

08540

For additional information regarding sites, Princeton

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT04174365 - Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter